These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 23831734)

  • 1. Impact of regurgitation on health-related quality of life in gastro-oesophageal reflux disease before and after short-term potent acid suppression therapy.
    Kahrilas PJ; Jonsson A; Denison H; Wernersson B; Hughes N; Howden CW
    Gut; 2014 May; 63(5):720-6. PubMed ID: 23831734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients.
    Bytzer P; van Zanten SV; Mattsson H; Wernersson B
    Aliment Pharmacol Ther; 2012 Oct; 36(7):635-43. PubMed ID: 22860764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
    Peura DA; Pilmer B; Hunt B; Mody R; Perez MC
    Aliment Pharmacol Ther; 2013 Nov; 38(10):1303-11. PubMed ID: 24118079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regurgitation is less responsive to acid suppression than heartburn in patients with gastroesophageal reflux disease.
    Kahrilas PJ; Jonsson A; Denison H; Wernersson B; Hughes N; Howden CW
    Clin Gastroenterol Hepatol; 2012 Jun; 10(6):612-9. PubMed ID: 22343515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and clinical characteristics of refractoriness to optimal proton pump inhibitor therapy in non-erosive reflux disease.
    Ribolsi M; Cicala M; Zentilin P; Neri M; Mauro A; Efthymakis K; Petitti T; Savarino V; Penagini R
    Aliment Pharmacol Ther; 2018 Nov; 48(10):1074-1081. PubMed ID: 30294924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, multicenter study: on-demand versus continuous maintenance treatment with esomeprazole in patients with non-erosive gastroesophageal reflux disease.
    Bayerdörffer E; Bigard MA; Weiss W; Mearin F; Rodrigo L; Dominguez Muñoz JE; Grundling H; Persson T; Svedberg LE; Keeling N; Eklund S
    BMC Gastroenterol; 2016 Apr; 16():48. PubMed ID: 27080034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of either rapid healing or refractory reflux oesophagitis during treatment with potent acid suppression.
    Kahrilas PJ; Persson T; Denison H; Wernersson B; Hughes N; Howden CW
    Aliment Pharmacol Ther; 2014 Sep; 40(6):648-56. PubMed ID: 25039978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of life in acute and maintenance treatment of non-erosive and mild erosive gastro-oesophageal reflux disease.
    Pace F; Negrini C; Wiklund I; Rossi C; Savarino V;
    Aliment Pharmacol Ther; 2005 Aug; 22(4):349-56. PubMed ID: 16098002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis.
    Robinson M; Fitzgerald S; Hegedus R; Murthy A; Jokubaitis L;
    Aliment Pharmacol Ther; 2002 Mar; 16(3):445-54. PubMed ID: 11876697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of persistent, frequent regurgitation on quality of life in heartburn responders treated with acid suppression: a multinational primary care study.
    Kahrilas PJ; Howden CW; Wernersson B; Denison H; Nuevo J; Gisbert JP
    Aliment Pharmacol Ther; 2013 May; 37(10):1005-10. PubMed ID: 23557078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Algorithmic approach to patients presenting with heartburn and epigastric pain refractory to empiric proton pump inhibitor therapy.
    Roorda AK; Marcus SN; Triadafilopoulos G
    Dig Dis Sci; 2011 Oct; 56(10):2871-8. PubMed ID: 21512760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic influence of Barrett's oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease (GORD) and symptom resolution in non-erosive GORD: report from the ProGORD study.
    Malfertheiner P; Lind T; Willich S; Vieth M; Jaspersen D; Labenz J; Meyer-Sabellek W; Junghard O; Stolte M
    Gut; 2005 Jun; 54(6):746-51. PubMed ID: 15888776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of heartburn resolution and erosive esophagitis in patients with GERD.
    Orlando RC; Monyak JT; Silberg DG
    Curr Med Res Opin; 2009 Sep; 25(9):2091-102. PubMed ID: 19601705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of and impact of pantoprazole on nocturnal heartburn and associated sleep complaints in patients with erosive esophagitis.
    Kindt S; Imschoot J; Tack J
    Dis Esophagus; 2011 Nov; 24(8):531-7. PubMed ID: 21418126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan.
    Miwa H; Sasaki M; Furuta T; Koike T; Habu Y; Ito M; Fujiwara Y; Wada T; Nagahara A; Hongo M; Chiba T; Kinoshita Y;
    Aliment Pharmacol Ther; 2007 Jul; 26(1):69-77. PubMed ID: 17555423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heartburn and regurgitation have different impacts on life quality of patients with gastroesophageal reflux disease.
    Lee SW; Lien HC; Lee TY; Yang SS; Yeh HJ; Chang CS
    World J Gastroenterol; 2014 Sep; 20(34):12277-82. PubMed ID: 25232262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.
    van Pinxteren B; Sigterman KE; Bonis P; Lau J; Numans ME
    Cochrane Database Syst Rev; 2010 Nov; (11):CD002095. PubMed ID: 21069670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.
    Sigterman KE; van Pinxteren B; Bonis PA; Lau J; Numans ME
    Cochrane Database Syst Rev; 2013 May; 2013(5):CD002095. PubMed ID: 23728637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease.
    Dent J; Kahrilas PJ; Hatlebakk J; Vakil N; Denison H; Franzén S; Lundborg P
    Am J Gastroenterol; 2008 Jan; 103(1):20-6. PubMed ID: 18184117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of structured follow-up and of more effective acid inhibitory treatment in the management of GORD patients in a Swedish primary-care setting: a randomized, open-label study.
    Ekesbo R; Sjöstedt S; Sörngård H
    Clin Drug Investig; 2011; 31(3):181-9. PubMed ID: 21288053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.